RenovoRx to Present TAMP Therapy Platform Pancreatic Cancer PET/CT Findings at 2026 Society of Interventional Radiology Annual Scientific Meeting

Reuters
Yesterday
RenovoRx to Present TAMP Therapy Platform Pancreatic Cancer PET/CT Findings at 2026 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx Inc. said a clinical data abstract from Moffitt Cancer Center on metabolic response observations after chemotherapeutic delivery via its TAMP (Trans-Arterial Micro-Perfusion) therapy platform in locally advanced pancreatic cancer was accepted for presentation at the 2026 Society of Interventional Radiology Annual Scientific Meeting, to be held April 11-15, 2026, in Toronto, Ontario, with the presentation scheduled for April 13, 2026. Event-related materials: https://d1io3yog0oux5.cloudfront.net/_9d8563855964dc3f9fbefdae77b76b08/renovorx/news/2026-02-26_RenovoRx_Announces_Acceptance_of_Clinical_Data_149.pdf

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10